- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IO BIOTECH Aktie jetzt für 0€ handeln | |||||
| 14:36 | IO Biotech GAAP EPS of -$0.13 beats by $0.25 | 1 | Seeking Alpha | ||
| 14:12 | IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights | 167 | GlobeNewswire (Europe) | Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, although... ► Artikel lesen | |
| 14:10 | IO Biotech, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13:10 | IO Biotech, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 07.11. | IO Biotech presents preclinical data for new cancer vaccine candidates | 1 | Investing.com | ||
| 07.11. | IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) | 1 | GlobeNewswire (USA) | ||
| 20.10. | IO Biotech Reveals Positive Phase 3 Results For Cylembio Plus Keytruda In Advanced Melanoma | 718 | AFX News | KENILWORTH (NJ) (dpa-AFX) - IO Biotech (IOBT), a clinical-stage biopharmaceutical company focused on cancer vaccines, Monday reported positive phase 3 results for Cylembio, in combination with... ► Artikel lesen | |
| 20.10. | IO Biotech: Kombinationsimpfstoff bei Melanom verfehlt statistische Signifikanz knapp | 1 | Investing.com Deutsch | ||
| 20.10. | IO Biotech's melanoma vaccine combination narrowly misses primary endpoint | 2 | Investing.com | ||
| 20.10. | IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 | 133 | GlobeNewswire (Europe) | Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression... ► Artikel lesen | |
| 29.09. | IO Biotech stock rating downgraded to Hold by TD Cowen on FDA setback | 9 | Investing.com | ||
| 29.09. | H.C. Wainwright stuft IO Biotech nach Studienverzögerungen auf "Neutral" herab | 1 | Investing.com Deutsch | ||
| 29.09. | IO Biotech stock downgraded to Neutral by H.C. Wainwright on trial delays | 2 | Investing.com | ||
| 29.09. | IO Biotech stock plummets after FDA recommends against BLA submission | 1 | Investing.com | ||
| 29.09. | IO Biotech: Aktie bricht nach negativem FDA-Votum für Krebsimpfstoff ein | 10 | Investing.com Deutsch | ||
| 29.09. | FDA recommends against IO Biotech's BLA for melanoma vaccine | 2 | Investing.com | ||
| 29.09. | IO Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.09. | IO Biotech Provides Update Following Pre-BLA Meeting with FDA | 154 | GlobeNewswire (Europe) | FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for... ► Artikel lesen | |
| 23.09. | IO Biotech stellt auf ESMO-Kongress Phase-3-Daten zu Melanom-Impfstoff vor | 3 | Investing.com Deutsch | ||
| 23.09. | IO Biotech to present phase 3 melanoma vaccine data at ESMO | 5 | Investing.com |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 3,884 | -1,27 % | Valneva-Aktie sorgt für Bewegung - Investoren achten auf jedes Signal!!! | ||
| BIOFRONTERA | 2,750 | +1,48 % | Biofrontera GAAP EPS of -$0.62, revenue of $6.98M | ||
| CRISPR THERAPEUTICS | 43,600 | -0,91 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in... ► Artikel lesen | |
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| BIONXT SOLUTIONS | 0,470 | -1,05 % | Übernahmekampf bei Novo Nordisk und Pfizer! BioNxt Solutions das nächste Ziel? | Wer übernimmt Metsera? Darüber streiten derzeit Novo Nordisk und Pfizer. Beide Pharmariesen wollen sich mit der Übernahme den Zugriff auf eine neue Generation von Stoffwechseltherapien sichern, die... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,378 | -0,94 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| BIO-GATE | 0,705 | -5,37 % | Bio-Gate: Deutliche Verbesserungen - und noch viel Potenzial | Das Management von Bio-Gate hat nach Darstellung von SMC-Research für das laufende Jahr deutliche Verbesserungen bei Umsatz und Ergebnis in Aussicht gestellt, wenn keine unerwarteten Projektverschiebungen... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,476 | -8,11 % | Defence Therapeutics Inc.: Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs | Montreal, Quebec--(Newsfile Corp. - November 6, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,428 | +2,90 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,881 | 0,00 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 | Once issued, this new U.S. patent covers the use of CardiolRx and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,960 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific... ► Artikel lesen | |
| ATAI BECKLEY | 3,549 | +0,08 % | AtaiBeckley N.V.: AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) Reported positive topline... ► Artikel lesen | |
| IMMUNITYBIO | 1,698 | -1,02 % | ImmunityBio: Zwischen Hype und Hoffnung | Die Aktie von ImmunityBio hat in den vergangenen eineinhalb Jahren deutlich an Wert verloren, nachdem Finanzierungsbedarf zu einer erheblichen Verwässerung führte. Dennoch rückt das Unternehmen dank... ► Artikel lesen | |
| ONCO-INNOVATIONS | 1,050 | +0,96 % | Inka Health, Tochter von Onco-Innovations, veröffentlicht Rahmenwerk zur Transportabilität von Real-World Evidence und der Verwendung in der Bewertung von Gesundheitstechnologien | Vancouver, Kanada - 7. November 2025 / IRW-Press / Onco-Innovations Limited (CBOE CA:
ONCO) (FWB: W1H, WKN: A3EKSZ)(OTCQB: ONNVF) ("Onco"
oder das "Unternehmen") freut sich bekannt zu geben... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 2,049 | -1,30 % | IOVANCE BIOTHERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans |
Das Unternehmen IO BIOTECH INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,807 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IO BIOTECH INC finden Sie auf Wallstreet Online.